allfeeds.ai

 

Treating Cancer Without Compromise  

Treating Cancer Without Compromise

How you ever wondered how a cancer drug comes to market? How does it get approved? And, do the regulations work? Where is the funding comes from? We will give you a behind the scenes look at TYME, an emerging Biotech company on the Nasdaq, our team, our doctors, out success stories, and much more.

Author: TYME Technologies

Have you ever wondered how a cancer drug comes to market? How does it get FDA approval? And, do the regulations work? Where does the funding come from? We will give you a behind the scenes look at TYME, an emerging biotech company on the NASDAQ, our team, our doctors, our success stories, and much more.
Be a guest on this podcast

Language: en

Genres: Health & Fitness, Medicine

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it


Get all podcast data

Listen Now...

Episode 6: Meet Junny Rivera-Ahmed
Thursday, 19 March, 2020

Junny is the President of The Joseph Ahmed Foundation (JAF), a 501(c)3 non-profit organization that was founded in 2016 by the family of Joseph Ahmed, who lost his courageous battle with Ewing’s Sarcoma eight months after his diagnosis on September 1, 2014, at the age of 16. Through their tragic loss and grief, Joseph’s loved ones established the Joseph Ahmed Foundation. Junny and her husband and co-President, Tharwat share more about their mission, resources, and ways to get involved.

 

We also recommend:


Kannst Du mich hören?

Cancer research - Medical Smart Bomb
Deakin University

GRACEcast ALL Subjects audio and video
cancerGRACE - H. Jack West, MD

Holistic Vets
Tracie Hotchner

Ytligheter
Akademikliniken

HealthCetera
HealthCetera, HealthCetera podcast by Senior Producers Diana J. Mason and Barbara Glickstein

Weight Loss for Busy Physicians | Helping Women Physicians Lose Weight for the Last Time
Katrina Ubell, MD Master Certified Life and Weight Loss Coach

Stories from Expo
EMS World

The Health In Harlem Podcast
healthinharlem

Cannabis Talk with Alicia
Alicia

Helsesekretærpodden

The Lancet Oncology in conversation with
The Lancet Group